Use of histone deacetylase inhibitors (HDACis) in pancreatic ductal adenocarcinoma (PDAC): A narrative review

[1] Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J Clin 72, 7–33 (2022) SiegelR. L. MillerK. D. FuchsH. E. JemalA. Cancer statistics, 2022 CA Cancer J Clin 72 7 33 2022 Search in Google Scholar

[2] Schouten, T. J. et al. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Ann Surg Oncol 29, 5988–5999 (2022) SchoutenT. J. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer Ann Surg Oncol 29 5988 5999 2022 Search in Google Scholar

[3] Balaban, E. P., Mangu, P. B. & Yee, N. S. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 13, 265–269 (2016) BalabanE. P. ManguP. B. YeeN. S. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary J Oncol Pract 13 265 269 2016 Search in Google Scholar

[4] Singh, R. R. & O’Reilly, E. M. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs vol. 80 647–669 Preprint at https://doi.org/10.1007/s40265-020-01304-0 (2020) SinghR. R. O’ReillyE. M. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma Drugs 80 647 669 Preprint at https://doi.org/10.1007/s40265-020-01304-0 2020 Search in Google Scholar

[5] Elrakaybi, A., Ruess, D. A., Lübbert, M., Quante, M. & Becker, H. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. Cancers vol. 14 Preprint at https://doi.org/10.3390/cancers14235926 (2022) ElrakaybiA. RuessD. A. LübbertM. QuanteM. BeckerH. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment Cancers 14 Preprint at https://doi.org/10.3390/cancers14235926 2022 Search in Google Scholar

[6] Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G. & Karamouzis, M. V. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World Journal of Gastrointestinal Oncology vol. 12 173–181 Preprint at https://doi.org/10.4251/wjgo.v12.i2.173 (2020) SarantisP. KoustasE. PapadimitropoulouA. PapavassiliouA. G. KaramouzisM. V. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy World Journal of Gastrointestinal Oncology 12 173 181 Preprint at https://doi.org/10.4251/wjgo.v12.i2.173 2020 Search in Google Scholar

[7] Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 7–30 (2020) SiegelR. L. MillerK. D. JemalA. Cancer statistics, 2020 CA Cancer J Clin 70 7 30 2020 Search in Google Scholar

[8] Von Hoff, D. D. et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine 369, 1691–1703 (2013) Von HoffD. D. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine New England Journal of Medicine 369 1691 1703 2013 Search in Google Scholar

[9] Adamska, A. et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul 68, 77–87 (2018) AdamskaA. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer Adv Biol Regul 68 77 87 2018 Search in Google Scholar

[10] Sinn, M. et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology 35, 3330–3337 (2017) SinnM. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial Journal of Clinical Oncology 35 3330 3337 2017 Search in Google Scholar

[11] Conroy, T. et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine 379, 2395–2406 (2018) ConroyT. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer New England Journal of Medicine 379 2395 2406 2018 Search in Google Scholar

[12] Ma, W. W. & Hidalgo, M. The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer. Clinical Cancer Research 19, 5572–5579 (2013) MaW. W. HidalgoM. The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer Clinical Cancer Research 19 5572 5579 2013 Search in Google Scholar

[13] Digiuseppe, J. A., Redston, M. S., Yeo, C. J., Kern, S. E. & Hruban, R. H. Communication P53-Independent Expression of the Cyclin-Dependent Kinase Inhibitor P21 in Pancreatic Carcinoma. American journal of Pathology vol. 147 (1995) DigiuseppeJ. A. RedstonM. S. YeoC. J. KernS. E. HrubanR. H. Communication P53-Independent Expression of the Cyclin-Dependent Kinase Inhibitor P21 in Pancreatic Carcinoma American journal of Pathology 147 1995 Search in Google Scholar

[14] Dardare, J., Witz, A., Merlin, J. L., Gilson, P. & Harlé, A. SMAD4 and the TGFB pathway in patients with pancreatic ductal adenocarcinoma. International Journal of Molecular Sciences vol. 21 Preprint at https://doi.org/10.3390/ijms21103534 (2020) DardareJ. WitzA. MerlinJ. L. GilsonP. HarléA. SMAD4 and the TGFB pathway in patients with pancreatic ductal adenocarcinoma International Journal of Molecular Sciences 21 Preprint at https://doi.org/10.3390/ijms21103534 2020 Search in Google Scholar

[15] Bartsch, D. K. et al. CDKN2A Germline Mutations in Familial Pancreatic Cancer. (2002) doi:10.1097/01.SLA0000036393.89509.4E BartschD. K. CDKN2A Germline Mutations in Familial Pancreatic Cancer 2002 10.1097/01.SLA0000036393.89509.4E Open DOISearch in Google Scholar

[16] Lomberk, G. et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun 9, (2018) LomberkG. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes Nat Commun 9 2018 Search in Google Scholar

[17] Hayashi, A., Hong, J. & Iacobuzio-Donahue, C. A. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 18, 469–481 (2021) HayashiA. HongJ. Iacobuzio-DonahueC. A. The pancreatic cancer genome revisited Nat Rev Gastroenterol Hepatol 18 469 481 2021 Search in Google Scholar

[18] Montalto, F. I. & De Amicis, F. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells vol. 9 Preprint at https://doi.org/10.3390/cells9122648 (2020) MontaltoF. I. De AmicisF. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma Cells 9 Preprint at https://doi.org/10.3390/cells9122648 2020 Search in Google Scholar

[19] Goodwin, C. M. et al. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer Res 83, 141–157 (2023) GoodwinC. M. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer Cancer Res 83 141 157 2023 Search in Google Scholar

[20] Jenke, R., Reßing, N., Hansen, F. K., Aigner, A. & Büch, T. cancers Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers (Basel) 13, 634 (2021) JenkeR. ReßingN. HansenF. K. AignerA. BüchT. cancers Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives Cancers (Basel) 13 634 2021 Search in Google Scholar

[21] Licht, J. D. & Bennett, R. L. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clinical Epigenetics vol. 13 Preprint at https://doi.org/10.1186/s13148-021-01100-x (2021) LichtJ. D. BennettR. L. Leveraging epigenetics to enhance the efficacy of immunotherapy Clinical Epigenetics 13 Preprint at https://doi.org/10.1186/s13148-021-01100-x 2021 Search in Google Scholar

[22] Knoche, S. M. et al. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. PLoS One 17, (2022) KnocheS. M. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer PLoS One 17 2022 Search in Google Scholar

[23] Simões-Pires, C. et al. HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs? Molecular Neurodegeneration vol. 8 Preprint at https://doi.org/10.1186/1750-1326-8-7 (2013) Simões-PiresC. HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs? Molecular Neurodegeneration 8 Preprint at https://doi.org/10.1186/1750-1326-8-7 2013 Search in Google Scholar

[24] van Kampen, J. G. M. et al. Epigenetic targeting in pancreatic cancer. Cancer Treat Rev 40, 656–664 (2014) van KampenJ. G. M. Epigenetic targeting in pancreatic cancer Cancer Treat Rev 40 656 664 2014 Search in Google Scholar

[25] Goto, K. et al. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Sci Rep 6, 38407 (2016) GotoK. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study Sci Rep 6 38407 2016 Search in Google Scholar

[26] Sun, T. et al. Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells. J Cancer 10, 5638–5645 (2019) SunT. Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells J Cancer 10 5638 5645 2019 Search in Google Scholar

[27] Ritter, C. et al. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Sci Rep 6, 21678 (2016) RitterC. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma Sci Rep 6 21678 2016 Search in Google Scholar

[28] Ugurel, S. et al. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series. Cancer Immunology, Immunotherapy 68, 983–990 (2019) UgurelS. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series Cancer Immunology, Immunotherapy 68 983 990 2019 Search in Google Scholar

[29] Mustafa, A.-H. M. & Krämer, O. H. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. Pharmacol Rev 75, 35 (2023) MustafaA.-H. M. KrämerO. H. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer Pharmacol Rev 75 35 2023 Search in Google Scholar

[30] Ashry, R. et al. NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor. Cancers (Basel) 15, (2023) AshryR. NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor Cancers (Basel) 15 2023 Search in Google Scholar

[31] Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development. Cell 99, 247–257 (1999) OkanoM. BellD. W. HaberD. A. LiE. DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development Cell 99 247 257 1999 Search in Google Scholar

[32] Scourzic, L., Mouly, E. & Bernard, O. A. TET proteins and the control of cytosine demethylation in cancer. Genome Med 7, (2015) ScourzicL. MoulyE. BernardO. A. TET proteins and the control of cytosine demethylation in cancer Genome Med 7 2015 Search in Google Scholar

[33] Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415–428 (2002) JonesP. A. BaylinS. B. The fundamental role of epigenetic events in cancer Nat Rev Genet 3 415 428 2002 Search in Google Scholar

[34] Jeziorska, D. M. et al. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease. Proc Natl Acad Sci U S A 114, E7526–E7535 (2017) JeziorskaD. M. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease Proc Natl Acad Sci U S A 114 E7526 E7535 2017 Search in Google Scholar

[35] Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001) LanderE. S. Initial sequencing and analysis of the human genome Nature 409 860 921 2001 Search in Google Scholar

[36] Herman, J. G. & Baylin, S. B. Gene Silencing in Cancer in Association with Promoter Hypermethylation. New England Journal of Medicine 349, 2042–2054 (2003) HermanJ. G. BaylinS. B. Gene Silencing in Cancer in Association with Promoter Hypermethylation New England Journal of Medicine 349 2042 2054 2003 Search in Google Scholar

[37] Zhu, J. et al. Integrating genome and methylome data to identify candidate DNA methylation biomarkers for pancreatic cancer risk. Cancer Epidemiology Biomarkers and Prevention 30, 2079–2087 (2021) ZhuJ. Integrating genome and methylome data to identify candidate DNA methylation biomarkers for pancreatic cancer risk Cancer Epidemiology Biomarkers and Prevention 30 2079 2087 2021 Search in Google Scholar

[38] Ozturk, H. et al. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Dev Cell 57, 1331–1346.e9 (2022) OzturkH. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer Dev Cell 57 1331 1346.e9 2022 Search in Google Scholar

[39] Sato, N., Matsubayashi, H., Abe, T., Fukushima, N. & Goggins, M. Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling. Clinical Cancer Research 11, 4681–4688 (2005) SatoN. MatsubayashiH. AbeT. FukushimaN. GogginsM. Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling Clinical Cancer Research 11 4681 4688 2005 Search in Google Scholar

[40] Eyres, M. et al. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Gastroenterology 161, 653–668.e16 (2021) EyresM. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes Gastroenterology 161 653 668.e16 2021 Search in Google Scholar

[41] Xiao, Q. et al. Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation. Cancer Res 76, 5395–5404 (2016) XiaoQ. Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation Cancer Res 76 5395 5404 2016 Search in Google Scholar

[42] Zhang, M. et al. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Signal Transduct Target Ther 6, (2021) ZhangM. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism Signal Transduct Target Ther 6 2021 Search in Google Scholar

[43] Tang, R.-Z. et al. DNA methyltransferase 1 and Krüppel-like factor 4 axis regulates macrophage inflammation and atherosclerosis. J Mol Cell Cardiol 128, 11–24 (2019) TangR.-Z. DNA methyltransferase 1 and Krüppel-like factor 4 axis regulates macrophage inflammation and atherosclerosis J Mol Cell Cardiol 128 11 24 2019 Search in Google Scholar

[44] Mees, S. T. et al. EP300—A miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 126, 114–124 (2010) MeesS. T. EP300—A miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas Int J Cancer 126 114 124 2010 Search in Google Scholar

[45] Cai, M. H. et al. Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine. Sci Rep 8, (2018) CaiM. H. Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine Sci Rep 8 2018 Search in Google Scholar

[46] Klieser, E. et al. Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy. World J Gastrointest Oncol 7, 473–483 (2015) KlieserE. Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy World J Gastrointest Oncol 7 473 483 2015 Search in Google Scholar

[47] Brand, M. et al. Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions. ACS Chem Biol 10, 22–39 (2015) BrandM. Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions ACS Chem Biol 10 22 39 2015 Search in Google Scholar

[48] Donati, B., Lorenzini, E. & Ciarrocchi, A. BRD4 and Cancer: Going beyond transcriptional regulation. Molecular Cancer vol. 17 Preprint at https://doi.org/10.1186/s12943-018-0915-9 (2018) DonatiB. LorenziniE. CiarrocchiA. BRD4 and Cancer: Going beyond transcriptional regulation Molecular Cancer 17 Preprint at https://doi.org/10.1186/s12943-018-0915-9 2018 Search in Google Scholar

[49] Shi, J. & Vakoc, C. R. The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition. Molecular Cell vol. 54 728–736 Preprint at https://doi.org/10.1016/j.molcel.2014.05.016 (2014) ShiJ. VakocC. R. The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition Molecular Cell 54 728 736 Preprint at https://doi.org/10.1016/j.molcel.2014.05.016 2014 Search in Google Scholar

[50] Greer, E. L. & Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nature Reviews Genetics vol. 13 343–357 Preprint at https://doi.org/10.1038/nrg3173 (2012) GreerE. L. ShiY. Histone methylation: A dynamic mark in health, disease and inheritance Nature Reviews Genetics 13 343 357 Preprint at https://doi.org/10.1038/nrg3173 2012 Search in Google Scholar

[51] Chen, Y. et al. The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal Transduction and Targeted Therapy vol. 5 Preprint at https://doi.org/10.1038/s41392-020-00252-1 (2020) ChenY. The role of histone methylation in the development of digestive cancers: a potential direction for cancer management Signal Transduction and Targeted Therapy 5 Preprint at https://doi.org/10.1038/s41392-020-00252-1 2020 Search in Google Scholar

[52] Benitz, S. et al. Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis. Gut 68, 2007 (2019) BenitzS. Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis Gut 68 2007 2019 Search in Google Scholar

[53] Andricovich, J. et al. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell 33, 512–526.e8 (2018) AndricovichJ. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors Cancer Cell 33 512 526.e8 2018 Search in Google Scholar

[54] Rao, R. A. et al. Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming. Sci Rep 5, (2015) RaoR. A. Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming Sci Rep 5 2015 Search in Google Scholar

[55] Ougolkov, A. V., Bilim, V. N. & Billadeau, D. D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clinical Cancer Research 14, 6790–6796 (2008) OugolkovA. V. BilimV. N. BilladeauD. D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2 Clinical Cancer Research 14 6790 6796 2008 Search in Google Scholar

[56] Toll, A. D. et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol 41, 1205–1209 (2010) TollA. D. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma Hum Pathol 41 1205 1209 2010 Search in Google Scholar

[57] Han, T. et al. EZH2 Promotes Cell Migration and Invasion but Not Alters Cell Proliferation by Suppressing E-Cadherin, Partly through Association with MALAT-1 in Pancreatic Cancer. Oncotarget vol. 7 www.impactjournals.com/oncotarget/ HanT. EZH2 Promotes Cell Migration and Invasion but Not Alters Cell Proliferation by Suppressing E-Cadherin, Partly through Association with MALAT-1 in Pancreatic Cancer Oncotarget 7 www.impactjournals.com/oncotarget/ Search in Google Scholar

[58] Aghdassi, A. et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61, 439 (2012) AghdassiA. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer Gut 61 439 2012 Search in Google Scholar

[59] Song, Y., Washington, M. K. & Crawford, H. C. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70, 2115–2125 (2010) SongY. WashingtonM. K. CrawfordH. C. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer Cancer Res 70 2115 2125 2010 Search in Google Scholar

[60] Roe, J. S. et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170, 875–888.e20 (2017) RoeJ. S. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis Cell 170 875 888.e20 2017 Search in Google Scholar

[61] Hessmann, E., Johnsen, S. A., Siveke, J. T. & Ellenrieder, V. Epigenetic treatment of pancreatic cancer: Is there a therapeutic perspective on the horizon? Gut 66, 168–179 (2017) HessmannE. JohnsenS. A. SivekeJ. T. EllenriederV. Epigenetic treatment of pancreatic cancer: Is there a therapeutic perspective on the horizon? Gut 66 168 179 2017 Search in Google Scholar

[62] Roca, M. S. et al. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Journal of Experimental and Clinical Cancer Research 41, (2022) RocaM. S. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation Journal of Experimental and Clinical Cancer Research 41 2022 Search in Google Scholar

[63] Romeo, M. A. et al. Acetylation increases expression, interaction with TRAPPC4 and surface localization of PD-L1. Discover Oncology 14, (2023) RomeoM. A. Acetylation increases expression, interaction with TRAPPC4 and surface localization of PD-L1 Discover Oncology 14 2023 Search in Google Scholar

[64] Qu, L. et al. The nuclear transportation of PD-L1 and the function in tumor immunity and progression. Cancer Immunology, Immunotherapy 71, 2313–2323 (2022) QuL. The nuclear transportation of PD-L1 and the function in tumor immunity and progression Cancer Immunology, Immunotherapy 71 2313 2323 2022 Search in Google Scholar

[65] Xiong, W., Gao, Y., Wei, W. & Zhang, J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer 7, 837–846 (2021) XiongW. GaoY. WeiW. ZhangJ. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy Trends Cancer 7 837 846 2021 Search in Google Scholar

[66] Zeng, Y. et al. MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Oncogene 41, 3859–3875 (2022) ZengY. MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer Oncogene 41 3859 3875 2022 Search in Google Scholar

[67] Kuo, T. L., Cheng, K. H., Chen, L. T. & Hung, W. C. ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance. iScience 26, (2023) KuoT. L. ChengK. H. ChenL. T. HungW. C. ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance iScience 26 2023 Search in Google Scholar

[68] Russell, M. A. et al. HLA Class II Antigen Processing and Presentation Pathway Components Demonstrated by Transcriptome and Protein Analyses of Islet β-Cells From Donors With Type 1 Diabetes. Diabetes 68, 988–1001 (2019) RussellM. A. HLA Class II Antigen Processing and Presentation Pathway Components Demonstrated by Transcriptome and Protein Analyses of Islet β-Cells From Donors With Type 1 Diabetes Diabetes 68 988 1001 2019 Search in Google Scholar

[69] Sixto-López, Y. et al. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines. Sci Rep 10, (2020) Sixto-LópezY. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines Sci Rep 10 2020 Search in Google Scholar

[70] Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132, 10842–10846 (2010) ButlerK. V. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J Am Chem Soc 132 10842 10846 2010 Search in Google Scholar

[71] Kong, Y. et al. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol Cancer Ther 10, 1591–1599 (2011) KongY. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor Mol Cancer Ther 10 1591 1599 2011 Search in Google Scholar

[72] Estiu, G. et al. On the inhibition of histone deacetylase 8. Bioorg Med Chem 18, 4103–4110 (2010) EstiuG. On the inhibition of histone deacetylase 8 Bioorg Med Chem 18 4103 4110 2010 Search in Google Scholar

[73] Charrier, C. et al. Synthesis and Modeling of New Benzofuranone Histone Deacetylase Inhibitors that Stimulate Tumor Suppressor Gene Expression. J Med Chem 52, 3112–3115 (2009) CharrierC. Synthesis and Modeling of New Benzofuranone Histone Deacetylase Inhibitors that Stimulate Tumor Suppressor Gene Expression J Med Chem 52 3112 3115 2009 Search in Google Scholar

[74] Khochbin, S., Verdel, A., Lemercier, C. & Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11, 162–166 (2001) KhochbinS. VerdelA. LemercierC. Seigneurin-BernyD. Functional significance of histone deacetylase diversity Curr Opin Genet Dev 11 162 166 2001 Search in Google Scholar

[75] Wang, D.-F., Helquist, P., Wiech, N. L. & Wiest, O. Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases. J Med Chem 48, 6936–6947 (2005) WangD.-F. HelquistP. WiechN. L. WiestO. Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases J Med Chem 48 6936 6947 2005 Search in Google Scholar

[76] Mazur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med 21, 1163–1171 (2015) MazurP. K. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma Nat Med 21 1163 1171 2015 Search in Google Scholar

[77] Maietta, I. et al. Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells. Pharmaceuticals 15, (2022) MaiettaI. Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells Pharmaceuticals 15 2022 Search in Google Scholar

[78] Bai, J., Demirjian, A., Sui, J., Marasco, W. & Callery, M. P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348, 1245–1253 (2006) BaiJ. DemirjianA. SuiJ. MarascoW. CalleryM. P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells Biochem Biophys Res Commun 348 1245 1253 2006 Search in Google Scholar

[79] Christmas, B. J. et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res 6, 1561–1577 (2018) ChristmasB. J. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs Cancer Immunol Res 6 1561 1577 2018 Search in Google Scholar

[80] Poklepovic, A. S. et al. A phase 1 study of neoadjuvant chemotherapy followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in pancreatic cancer. Journal of Clinical Oncology 39, e16268–e16268 (2021) PoklepovicA. S. A phase 1 study of neoadjuvant chemotherapy followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in pancreatic cancer Journal of Clinical Oncology 39 e16268 e16268 2021 Search in Google Scholar

[81] Streubel, G. et al. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Sci Rep 11, (2021) StreubelG. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma Sci Rep 11 2021 Search in Google Scholar

[82] Wang, Z. et al. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Cancer Cell 37, 834–849.e13 (2020) WangZ. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy Cancer Cell 37 834 849.e13 2020 Search in Google Scholar

[83] Chan, E. et al. Phase i trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiotherapy and Oncology 119, 312–318 (2016) ChanE. Phase i trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer Radiotherapy and Oncology 119 312 318 2016 Search in Google Scholar

[84] Ubbert, M. L. ¨ et al. MD 12,13 ; Hans-Walter Lindemann, MD 14 ; Carsten Müller-Tidow, MD 5,15,16 ; Gerhard Heil. J Clin Oncol 17, 257–270 Ubbert, M. L. ¨ et al. MD 12,13 ; Hans-Walter Lindemann, MD 14 ; Carsten Müller-Tidow, MD 5,15,16 ; Gerhard Heil. J Clin Oncol 17 257 270 Search in Google Scholar

[85] Meier, R. et al. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation. Blood Cancer J 12, (2022) MeierR. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation Blood Cancer J 12 2022 Search in Google Scholar

[86] Li, Y. et al. Alterations of specific chromatin conformation affect ATRA-induced leukemia cell differentiation. Cell Death Dis 9, (2018) LiY. Alterations of specific chromatin conformation affect ATRA-induced leukemia cell differentiation Cell Death Dis 9 2018 Search in Google Scholar

[87] Trus, M. R. et al. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 19, 1161–1168 (2005) TrusM. R. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells Leukemia 19 1161 1168 2005 Search in Google Scholar

[88] Luu, T. et al. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemother Pharmacol 84, 1201–1208 (2019) LuuT. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial Cancer Chemother Pharmacol 84 1201 1208 2019 Search in Google Scholar

[89] Neureiter, D. et al. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 42, 103–116 (2007) NeureiterD. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models Scand J Gastroenterol 42 103 116 2007 Search in Google Scholar

[90] Guo, Z. et al. Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors. J Med Chem 65, 6573–6592 (2022) GuoZ. Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors J Med Chem 65 6573 6592 2022 Search in Google Scholar

[91] He, S. et al. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Angewandte Chemie International Edition 59, 3028–3032 (2020) HeS. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer Angewandte Chemie International Edition 59 3028 3032 2020 Search in Google Scholar

[92] Lassen, U. et al. A phase i study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 103, 12–17 (2010) LassenU. A phase i study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours Br J Cancer 103 12 17 2010 Search in Google Scholar

[93] Ikeda, M. et al. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Invest New Drugs 37, 109–117 (2019) IkedaM. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer Invest New Drugs 37 109 117 2019 Search in Google Scholar